Scientific Evidence

The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus: a multicenter US clinical experience study

Oct 2023

TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD. 

Author: Khara HS, et al.

Publication: Poster presentation (S600) at ACG 2023, Vancouver

Gene Expression Differences Identified in Skin Samples of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Oct 2023

Author: Farberg A, et al.

Publication: Poster, presented at the 2023 Fall Clinical Dermatology Conference®, Las Vegas, Nevada, October 19-22, 2023

The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients

Sep 2023

This study evaluates the performance of DecisionDx-Melanoma and the MSKCC nomogram in a head-to-head study in 465 patients withT1 or T2 tumors and known SLN status

Author: Tassavor M, et al.

Publication: Anticancer Research

A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center

Sep 2023

TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.

Author: Tseng D, et al.

Publication: Poster presentation (61) at AFS 2023, Dallas

The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial.

Sep 2023

In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.

Author: Cao F, Hanson A, Cook R, et al.

Publication: Poster at Psych Congress 2023

The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort

Aug 2023

This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.

Author: Villa NA, et al.

Publication: Diseases of the Esophagus

31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

Jun 2023

Study data from Castle Biosciences' collaboration with the National Cancer Institutes SEER program registries.

Author: Bailey CN, et al.

Publication: JCO-PO

Atypical melanocytic proliferation on sensitive preauricular check

Jun 2023

Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.

Multi-colored lesion with uncertain malignant potential

Jun 2023

Conflicting clinical and histopathological findings are resolved with the use of GEP test results.

Abnormally pigmented lesion with uncertain malignant potential

Jun 2023

With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.

Asymmetrical pigmented lesion with high clinical suspicion for melanoma

Jun 2023

A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.

Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis

Jun 2023

Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.